WHO has a unique combination of technical public health and scientific expertise, and a global operational footprint, with field offices in more than 150 countries. In 2020, this global, technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVI...D-19 public health response, from surveillance and laboratory testing to maintaining essential health services in the most vulnerable and fragile contexts.
more
1 February 2021 to 31 January 2022
A practitioner’s guide to the principles of COVID-19 vaccine communications.
The factors that lead people to make choices to take vaccines are nuanced and affected by how they see the world, their perceptions of the choices people like them will make, who they trust, their perceptions of risk,... consistency of message and convenience of actually getting the vaccine.
more
This strategic document is relevant to the diverse contexts that exist across the WHO European Region, and to countries implementing a wide range of national and subnational responses. The strategy is flexible and adaptable to national and subnational contexts and guides countries in rapidly bringin...g COVID-19 cases under control, and in preparing for a phased transition from a widespread transmission to a steady state of low-level or no transmission.
more
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
Published: April 26, 2017 https://doi.org/10.1371/journal.pone.0176004
The Guidance on National Deployment and Vaccination Planning is intended to help countries develop their plan for COVID-19 vaccine introduction.
In: Bonk M., Ulrichs T (eds). Global Health: Das Konzept der Globalen Gesundheit. Berlin: De Gruyter, 2021, pp. 523–556
Wohlstand, Gesundheit und Gesundheitsausgaben sind eng miteinander verknüpft. Im weltweiten Durchschnitt haben alle drei seit vielen Jahren stetig zugenommen. Im Vergleich hab...en Menschen in Ländern mit höheren Einkommen eine höhere Lebenserwartung. Die höchste Krankheitslast pro Mensch tritt in Ländern mit niedrigem Einkommen auf. Den größten Anteil an der gesamten globalen Krankheitslast haben Länder mit mittlerem Einkommen, in denen rund drei Viertel der Weltbevölkerung lebt. Im Mittel sind die Gesundheitsausgaben in Ländern mit höheren Einkommen insgesamt sowie pro Kopf höher als die Gesundheitsausgaben in Ländern mit niedrigeren Einkommen.
more
In: Bonk M., Ulrichs T. (eds). Global Health: Das Konzept der Globalen Gesundheit. Berlin: De Gruyter, 2021, pp. 557–580
This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on whic...h technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance. It addresses the most used sequencing technologies and their applications and proposes a central standardisation process to analyse and report the findings of SARS-CoV-2 genetic characterisations.
more
Vaccines 2021, 9(2), 160; https://doi.org/10.3390/vaccines9020160
Revision for Field Review
J of Pharm Policy and Pract 14, 27 (2021). https://doi.org/10.1186/s40545-021-00309-8